Related Experiment Video
Updated: Apr 8, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.3K
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer
A E Ross1,2,3, A V D'Amico4, S J Freedland5
1Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Prostate Cancer and Prostatic Diseases
|July 1, 2015
Summary
Molecular tests like PTEN, Ki-67, Prolaris, ProMark, OncotypeDX Prostate, and Decipher aid in localized prostate cancer decisions. These assays help guide active surveillance, prognosis, and adjuvant radiation choices for improved patient care.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Localized prostate cancer understanding has grown with molecular testing.
- Multiple clinical assays are now available for tissue-based molecular testing.
Purpose of the Study:
- Review the molecular biology of localized prostate cancer.
- Evaluate currently available tissue-based molecular tests.
- Provide expert opinions on test utility in various clinical scenarios.
Main Methods:
- Literature review of studies on Ki-67, PTEN (IHC/FISH), ProMark, Prolaris, OncotypeDX Prostate, and Decipher.
- Analysis of test performance in localized prostate cancer.
Main Results:
- PTEN status, ProMark, or OncotypeDX Prostate may guide active surveillance for Gleason 6 or 3+4=7 disease.
- Ki-67 and Prolaris offer prognostic information for Gleason 7+ disease considering watchful waiting.
- Decipher testing can inform adjuvant radiation decisions for post-prostatectomy adverse pathology.
Conclusions:
- New molecular tests enhance decision-making for localized prostate cancer.
- Specific tests demonstrate utility in distinct clinical situations, optimizing patient management.
